You raised for our industry the most important question. Before we talk about what pharmacare is, we are designing something for a problem when we don't really know exactly what the problem is. Is it a coverage issue? Is it an access issue? Is it a combination of both? If somebody presents with the symptoms of a heart attack, you don't immediately cut them open and take a look at the heart. You try to figure out what really is going on in that person. We would do similarly. I think we should take a look and figure out what those numbers are.
The Romanow commission did a lot of great work, but that was almost 20 years ago. What do the statistics bear out? Where is the challenge? What is the opportunity here? Once we have a better handle as to what we are trying to address, then I think the solution will become a bit more evident.